NAVIDEA BIOPHARMACEUTICALS, INC.

2023 Q4 Form 10-Q Financial Statement

#000143774923032052 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.865M
YoY Change -16.0%
Cash & Equivalents $3.865M
Short-Term Investments
Other Short-Term Assets $146.6K
YoY Change -2.36%
Inventory $460.7K
Prepaid Expenses
Receivables $30.87K
Other Receivables $0.00
Total Short-Term Assets $4.503M
YoY Change -11.7%
LONG-TERM ASSETS
Property, Plant & Equipment $108.8K
YoY Change -26.98%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $11.77K
YoY Change -62.94%
Total Long-Term Assets $1.196M
YoY Change 3.21%
TOTAL ASSETS
Total Short-Term Assets $4.503M
Total Long-Term Assets $1.196M
Total Assets $5.699M
YoY Change -8.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.071M
YoY Change 19.1%
Accrued Expenses $3.859M
YoY Change -34.53%
Deferred Revenue
YoY Change
Short-Term Debt $1.249M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.979M
YoY Change -5.39%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities $700.3K
YoY Change -0.2%
Total Long-Term Liabilities $700.3K
YoY Change -71.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.979M
Total Long-Term Liabilities $700.3K
Total Liabilities $8.679M
YoY Change -20.56%
SHAREHOLDERS EQUITY
Retained Earnings -$385.9M
YoY Change 0.36%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.273M
YoY Change
Total Liabilities & Shareholders Equity $5.699M
YoY Change -8.94%

Cashflow Statement

Concept 2023 Q4 2023 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35076
dei Local Phone Number
LocalPhoneNumber
793-7500
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3778074 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6703145 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2131338 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
4823869 usd
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Entity Registrant Name
EntityRegistrantName
NAVIDEA BIOPHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
31-1080091
dei Entity Address Address Line1
EntityAddressAddressLine1
4995 Bradenton Avenue, Suite 240
dei Entity Address City Or Town
EntityAddressCityOrTown
Dublin
dei Entity Address State Or Province
EntityAddressStateOrProvince
OH
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
43017-3552
dei City Area Code
CityAreaCode
614
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0000810509
CY2022Q2 navb Share Purchase Right Shares Issuable Per Each Right
SharePurchaseRightSharesIssuablePerEachRight
0.001
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0 usd
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0 usd
CY2022Q3 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0 usd
navb Allocated Sharebased Compensation Expense Reversal
AllocatedSharebasedCompensationExpenseReversal
-3826 usd
CY2023Q3 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
dei Document Type
DocumentType
10-Q
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
NAVB
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
100084385
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3864822 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1995860 usd
CY2023Q3 navb Stock Subscriptions And Other Receivables
StockSubscriptionsAndOtherReceivables
30870 usd
CY2022Q4 navb Stock Subscriptions And Other Receivables
StockSubscriptionsAndOtherReceivables
630 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
460746 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
427344 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
146593 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
780110 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
4503031 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
3203944 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
733145 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
835845 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
624327 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
700498 usd
navb Grant And Other Revenue
GrantAndOtherRevenue
0 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
108818 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
135347 usd
CY2023Q3 navb Operating Lease Rightofuse Asset Gross
OperatingLeaseRightofuseAssetGross
24313 usd
CY2022Q4 navb Operating Lease Rightofuse Asset Gross
OperatingLeaseRightofuseAssetGross
107243 usd
CY2023Q3 navb Operating Lease Rightofuse Assets Accumulated Amortization
OperatingLeaseRightofuseAssetsAccumulatedAmortization
13751 usd
CY2022Q4 navb Operating Lease Rightofuse Assets Accumulated Amortization
OperatingLeaseRightofuseAssetsAccumulatedAmortization
86943 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10562 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20300 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1320428 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1215604 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
255819 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
215363 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1064609 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1000241 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11774 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11774 usd
CY2023Q3 us-gaap Assets
Assets
5698794 usd
CY2022Q4 us-gaap Assets
Assets
4371606 usd
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3848443 usd
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6456762 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
10427 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
18976 usd
CY2023Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
800000 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
800000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7978570 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9941889 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
269 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1312 usd
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
700000 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
700000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
8678839 usd
CY2022Q4 us-gaap Liabilities
Liabilities
12514916 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100084385
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
100084385
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32687666
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32687666
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
382345740 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
379343124 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-385909398 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-388002649 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-3272561 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-8435828 usd
CY2023Q3 us-gaap Minority Interest
MinorityInterest
292516 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
292518 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2980045 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-8143310 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5698794 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4371606 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7516 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14035 usd
CY2023Q3 navb Grant And Other Revenue
GrantAndOtherRevenue
0 usd
CY2022Q3 navb Grant And Other Revenue
GrantAndOtherRevenue
0 usd
navb Grant And Other Revenue
GrantAndOtherRevenue
51007 usd
CY2023Q3 us-gaap Revenues
Revenues
0 usd
CY2022Q3 us-gaap Revenues
Revenues
7516 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
65042 usd
CY2023Q3 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
0 usd
CY2022Q3 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
1432 usd
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
0 usd
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
1905 usd
CY2023Q3 navb Reserve For Expiring Inventory
ReserveForExpiringInventory
0 usd
CY2022Q3 navb Reserve For Expiring Inventory
ReserveForExpiringInventory
133006 usd
navb Reserve For Expiring Inventory
ReserveForExpiringInventory
0 usd
navb Reserve For Expiring Inventory
ReserveForExpiringInventory
133006 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
0 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
-126922 usd
us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Gross Profit
GrossProfit
-69869 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
829613 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1186419 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3203331 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4079661 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1301725 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3637450 usd
us-gaap Operating Expenses
OperatingExpenses
6981405 usd
us-gaap Operating Expenses
OperatingExpenses
10782806 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2131338 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4950791 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6981405 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-10852675 usd
CY2023Q3 us-gaap Investment Income Net
InvestmentIncomeNet
-102514 usd
CY2022Q3 us-gaap Investment Income Net
InvestmentIncomeNet
-765456 usd
us-gaap Investment Income Net
InvestmentIncomeNet
248671 usd
us-gaap Investment Income Net
InvestmentIncomeNet
-852702 usd
CY2023Q3 navb Gain Loss On Contract Amendment
GainLossOnContractAmendment
0 usd
CY2022Q3 navb Gain Loss On Contract Amendment
GainLossOnContractAmendment
0 usd
navb Gain Loss On Contract Amendment
GainLossOnContractAmendment
1226432 usd
navb Gain Loss On Contract Amendment
GainLossOnContractAmendment
0 usd
CY2023Q3 navb Gain Loss On Sale Of Nonfinancial Asset
GainLossOnSaleOfNonfinancialAsset
0 usd
CY2022Q3 navb Gain Loss On Sale Of Nonfinancial Asset
GainLossOnSaleOfNonfinancialAsset
0 usd
navb Gain Loss On Sale Of Nonfinancial Asset
GainLossOnSaleOfNonfinancialAsset
750000 usd
navb Gain Loss On Sale Of Nonfinancial Asset
GainLossOnSaleOfNonfinancialAsset
0 usd
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-185056 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-21487 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8422 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-183495 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10489 usd
CY2023Q3 navb Nonoperating Income Expense Including Equity Method Investments
NonoperatingIncomeExpenseIncludingEquityMethodInvestments
-124001 usd
CY2022Q3 navb Nonoperating Income Expense Including Equity Method Investments
NonoperatingIncomeExpenseIncludingEquityMethodInvestments
-757034 usd
navb Nonoperating Income Expense Including Equity Method Investments
NonoperatingIncomeExpenseIncludingEquityMethodInvestments
1856552 usd
navb Nonoperating Income Expense Including Equity Method Investments
NonoperatingIncomeExpenseIncludingEquityMethodInvestments
-841853 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2255339 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5707825 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5124853 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10347 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11694528 usd
CY2023Q3 us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
0 usd
CY2022Q3 us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
0 usd
us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
7425000 usd
us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
0 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-2255339 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-5707825 usd
us-gaap Profit Loss
ProfitLoss
2300147 usd
us-gaap Profit Loss
ProfitLoss
-11694528 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1 usd
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-0 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-4 usd
CY2023Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
-0 usd
CY2022Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
-0 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
68937 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
-0 usd
CY2023Q3 navb Preferred Stock Deemed Dividend
PreferredStockDeemedDividend
-0 usd
CY2022Q3 navb Preferred Stock Deemed Dividend
PreferredStockDeemedDividend
2037886 usd
navb Preferred Stock Deemed Dividend
PreferredStockDeemedDividend
138045 usd
navb Preferred Stock Deemed Dividend
PreferredStockDeemedDividend
2037886 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2255338 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7745711 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2093167 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13732410 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.02
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.25
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.09
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.45
CY2023Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
0
CY2022Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
0
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
0.12
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
0
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
99364154
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30732001
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60331296
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30404789
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-8143310 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
52348 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19669 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-1476330 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-9547623 usd
CY2023Q2 navb Stock Issued Under Credit Net Of Costs
StockIssuedUnderCreditNetOfCosts
600126 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1089000 usd
CY2023Q2 navb Stock Issued During Period Shares Partial Repayment Of Debt
StockIssuedDuringPeriodSharesPartialRepaymentOfDebt
1073600
CY2023Q2 navb Stock Issued During Period Value Issued For Director Fees
StockIssuedDuringPeriodValueIssuedForDirectorFees
338 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
33841 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
6031816 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-786584 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
-0 usd
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 usd
CY2023Q3 navb Stock Issued During Period Value Issued For Director Fees
StockIssuedDuringPeriodValueIssuedForDirectorFees
51531 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-2255339 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2980045 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
624743 usd
CY2022Q1 navb Stock Issued During Period Value Issued For Employee Bonuses
StockIssuedDuringPeriodValueIssuedForEmployeeBonuses
16965 usd
CY2022Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
44720 usd
CY2022Q1 navb Stock Issued During Period Value Issued For Director Fees
StockIssuedDuringPeriodValueIssuedForDirectorFees
6525 usd
CY2022Q1 navb Adjustments To Additional Paid In Capital Preferred Stock Cancelled Due To Settlement
AdjustmentsToAdditionalPaidInCapitalPreferredStockCancelledDueToSettlement
0 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
184850 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2987245 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2109442 usd
CY2022Q2 navb Stock Issued During Period Value Issued For Director Fees
StockIssuedDuringPeriodValueIssuedForDirectorFees
6450 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
40554 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-2999459 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4240647 usd
CY2022Q3 navb Stock Issued During Period Value Issued For Director Fees
StockIssuedDuringPeriodValueIssuedForDirectorFees
2950 usd
CY2022Q3 navb Stock Issued During Period Value Issued For Employee Bonuses
StockIssuedDuringPeriodValueIssuedForEmployeeBonuses
7882 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19740 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
41052 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-5707825 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4667116 usd
us-gaap Profit Loss
ProfitLoss
2300147 usd
us-gaap Profit Loss
ProfitLoss
-11694528 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-7425000 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-5124853 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-11694528 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
81717 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
69352 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
27241 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
91733 usd
us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
-1377 usd
us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
-64833 usd
us-gaap Inventory Write Down
InventoryWriteDown
0 usd
us-gaap Inventory Write Down
InventoryWriteDown
133006 usd
us-gaap Share Based Compensation
ShareBasedCompensation
-3826 usd
us-gaap Share Based Compensation
ShareBasedCompensation
266456 usd
navb Issuance Of Stock To Defined Contribution Plan For Employer Matching Contribution
IssuanceOfStockToDefinedContributionPlanForEmployerMatchingContribution
52348 usd
navb Issuance Of Stock To Defined Contribution Plan For Employer Matching Contribution
IssuanceOfStockToDefinedContributionPlanForEmployerMatchingContribution
44720 usd
navb Value Of Stock Issued To Employees
ValueOfStockIssuedToEmployees
0 usd
navb Value Of Stock Issued To Employees
ValueOfStockIssuedToEmployees
24847 usd
navb Value Of Stock Issued Under Longterm Incentive Plan
ValueOfStockIssuedUnderLongtermIncentivePlan
0 usd
navb Value Of Stock Issued Under Longterm Incentive Plan
ValueOfStockIssuedUnderLongtermIncentivePlan
19740 usd
navb Issuance Of Stock To Cash Payments Of Director Fees
IssuanceOfStockToCashPaymentsOfDirectorFees
51869 usd
navb Issuance Of Stock To Cash Payments Of Director Fees
IssuanceOfStockToCashPaymentsOfDirectorFees
15925 usd
navb Issuance Of Stock For Upfront Commitment Fee
IssuanceOfStockForUpfrontCommitmentFee
50000 usd
navb Issuance Of Stock For Upfront Commitment Fee
IssuanceOfStockForUpfrontCommitmentFee
0 usd
navb Gain Loss On Contract Amendment
GainLossOnContractAmendment
1226432 usd
navb Gain Loss On Contract Amendment
GainLossOnContractAmendment
-0 usd
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
750000 usd
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
-0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-185056 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-0 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
265896 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
126878 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
30240 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
62197 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
33402 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
175657 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-633517 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-953566 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-51905 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
317202 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1381887 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2727010 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-27095 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-266970 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
790644 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7280619 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6553440 usd
us-gaap Proceeds From Sale Of Other Productive Assets
ProceedsFromSaleOfOtherProductiveAssets
750000 usd
us-gaap Proceeds From Sale Of Other Productive Assets
ProceedsFromSaleOfOtherProductiveAssets
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15068 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
63086 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
336 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
106201 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
255224 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-629067 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-318310 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
1100000 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
6173000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
643759 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
300000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2500000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
-0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
14627 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
843613 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
453427 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1095514 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7241676 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations
-5556038 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations
369926 usd
navb Cash Provided By Used In Investing Activities Discontinued Operations1
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations1
7425000 usd
navb Cash Provided By Used In Investing Activities Discontinued Operations1
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations1
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1868962 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
369926 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1995860 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4230865 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3864822 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4600791 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>b.</b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Use of Estimates:</b> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> </td> </tr> </tbody></table>
navb Patent And Trademark Costs
PatentAndTrademarkCosts
106201 usd
navb Patent And Trademark Costs
PatentAndTrademarkCosts
255224 usd
navb Previously Capitalized Patent Costs Abandoned
PreviouslyCapitalizedPatentCostsAbandoned
1377 usd
navb Previously Capitalized Patent Costs Abandoned
PreviouslyCapitalizedPatentCostsAbandoned
64833 usd
navb Contract With Customer Payment Term Minimum
ContractWithCustomerPaymentTermMinimum
P15D
navb Contract With Customer Payment Term Maximum
ContractWithCustomerPaymentTermMaximum
P90D
CY2023Q3 navb Contract With Customer Transaction Price Of Royalties Using Expected Value Method
ContractWithCustomerTransactionPriceOfRoyaltiesUsingExpectedValueMethod
0 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7516 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14035 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.24
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
700000 usd
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
700000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
700000 usd
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
700000 usd
CY2023Q3 navb Contract With Customer Liability Revenue Deferred Related To Sublicense
ContractWithCustomerLiabilityRevenueDeferredRelatedToSublicense
0 usd
CY2022Q3 navb Contract With Customer Liability Revenue Deferred Related To Sublicense
ContractWithCustomerLiabilityRevenueDeferredRelatedToSublicense
0 usd
navb Contract With Customer Liability Revenue Deferred Related To Sublicense
ContractWithCustomerLiabilityRevenueDeferredRelatedToSublicense
0 usd
navb Contract With Customer Liability Revenue Deferred Related To Sublicense
ContractWithCustomerLiabilityRevenueDeferredRelatedToSublicense
100000 usd
CY2023Q3 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Modification Of Contract
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract
-0 usd
CY2022Q3 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Modification Of Contract
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract
-0 usd
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Modification Of Contract
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract
-0 usd
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Modification Of Contract
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract
100000 usd
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
700000 usd
CY2022Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
700000 usd
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
700000 usd
CY2022Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
700000 usd
CY2023Q3 navb Allocated Sharebased Compensation Expense Reversal
AllocatedSharebasedCompensationExpenseReversal
10347 usd
CY2022Q3 navb Allocated Sharebased Compensation Expense Reversal
AllocatedSharebasedCompensationExpenseReversal
41052 usd
navb Allocated Sharebased Compensation Expense Reversal
AllocatedSharebasedCompensationExpenseReversal
266456 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
702805
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.42
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y6M
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1339500
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.32
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1060465
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.73
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
4600
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
54.92
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
977240
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.57
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M6D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
457365
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.09
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y4M24D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8947 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0387 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M12D
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
125692 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M3D
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
27405 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
27405 usd
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
433341 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
399939 usd
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
131804 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
131804 usd
CY2023Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
131804 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
131804 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
460746 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
427344 usd
CY2022Q2 navb Difference Betweent Value Of Conversion Stocks
DifferenceBetweentValueOfConversionStocks
821250 usd
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
98424 usd
CY2022Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
120696 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
410653 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
208004 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1430000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
28340 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
43493 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
9443 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1355 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
10798 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
102 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
10696 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
10696 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y4M24D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1045 pure
us-gaap Operating Lease Payments
OperatingLeasePayments
28329 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
281668 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
624743 usd
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
175000000 usd
CY2022Q2 navb Share Purchase Right Ownership Percentage Threshold
SharePurchaseRightOwnershipPercentageThreshold
0.0499 pure
CY2022Q2 navb Share Purchase Right Ownership Percentage Threshold
SharePurchaseRightOwnershipPercentageThreshold
0.0499 pure
CY2022Q2 navb Share Purchase Right Ownership Percentage Trigger
SharePurchaseRightOwnershipPercentageTrigger
0.005 pure
CY2022Q2 navb Share Purchase Right Discount Percentage
SharePurchaseRightDiscountPercentage
0.50 pure
us-gaap Stock Issued During Period Shares Employee Benefit Plan
StockIssuedDuringPeriodSharesEmployeeBenefitPlan
163586
us-gaap Stock Issued During Period Shares Employee Benefit Plan
StockIssuedDuringPeriodSharesEmployeeBenefitPlan
53238
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
52348 usd
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
44720 usd
CY2023Q2 us-gaap Share Price
SharePrice
0.25
CY2023Q2 us-gaap Share Price
SharePrice
0.25
CY2023Q2 navb Accrued And Unpaid Dividends
AccruedAndUnpaidDividends
1058853 usd
CY2023Q2 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
1196900 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
23348906
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
829613 usd
CY2023Q3 navb Selling General And Administrative Expense Excluding Depreciation And Amortization
SellingGeneralAndAdministrativeExpenseExcludingDepreciationAndAmortization
1274698 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
27027 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2131338 usd
CY2023Q3 navb Nonoperating Income Expense Excluding Equity Investment Income
NonoperatingIncomeExpenseExcludingEquityInvestmentIncome
-124001 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2255339 usd
CY2022Q3 navb Grant And Other Revenue
GrantAndOtherRevenue
0 usd
CY2022Q3 us-gaap Revenues
Revenues
7516 usd
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
1432 usd
CY2022Q3 us-gaap Inventory Write Down
InventoryWriteDown
133006 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1186419 usd
CY2022Q3 navb Selling General And Administrative Expense Excluding Depreciation And Amortization
SellingGeneralAndAdministrativeExpenseExcludingDepreciationAndAmortization
3612747 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
24703 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4950791 usd
CY2022Q3 navb Nonoperating Income Expense Excluding Equity Investment Income
NonoperatingIncomeExpenseExcludingEquityInvestmentIncome
-757034 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-5707825 usd
CY2022Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14429 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3203331 usd
navb Selling General And Administrative Expense Excluding Depreciation And Amortization
SellingGeneralAndAdministrativeExpenseExcludingDepreciationAndAmortization
3696357 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
81717 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6981405 usd
navb Nonoperating Income Expense Excluding Equity Investment Income
NonoperatingIncomeExpenseExcludingEquityInvestmentIncome
1856552 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5124853 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15068 usd
navb Grant And Other Revenue
GrantAndOtherRevenue
51007 usd
us-gaap Revenues
Revenues
65042 usd
us-gaap Cost Of Revenue
CostOfRevenue
1905 usd
us-gaap Inventory Write Down
InventoryWriteDown
133006 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4079661 usd
navb Selling General And Administrative Expense Excluding Depreciation And Amortization
SellingGeneralAndAdministrativeExpenseExcludingDepreciationAndAmortization
6633793 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
69352 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-10852675 usd
navb Nonoperating Income Expense Excluding Equity Investment Income
NonoperatingIncomeExpenseExcludingEquityInvestmentIncome
-841853 usd
us-gaap Profit Loss
ProfitLoss
-11694528 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
63086 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
27027 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
24703 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
81717 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
69352 usd
us-gaap Interest Paid Net
InterestPaidNet
135248 usd
us-gaap Interest Paid Net
InterestPaidNet
81126 usd
us-gaap Stock Issued During Period Shares Employee Benefit Plan
StockIssuedDuringPeriodSharesEmployeeBenefitPlan
163586
us-gaap Stock Issued During Period Shares Employee Benefit Plan
StockIssuedDuringPeriodSharesEmployeeBenefitPlan
53238
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
52348 usd
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
44720 usd
navb Adjustments To Additional Paid In Capital Deemed Dividends
AdjustmentsToAdditionalPaidInCapitalDeemedDividends
138045 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
17503 usd

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
navb-20230930_cal.xml Edgar Link unprocessable
0001437749-23-032052-index-headers.html Edgar Link pending
0001437749-23-032052-index.html Edgar Link pending
0001437749-23-032052.txt Edgar Link pending
0001437749-23-032052-xbrl.zip Edgar Link pending
ex_596349.htm Edgar Link pending
ex_596350.htm Edgar Link pending
ex_596351.htm Edgar Link pending
ex_596352.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
navb-20230930.xsd Edgar Link pending
navb20230930_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
navb-20230930_def.xml Edgar Link unprocessable
navb-20230930_lab.xml Edgar Link unprocessable
navb-20230930_pre.xml Edgar Link unprocessable
navb20230930_10q_htm.xml Edgar Link completed
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending